Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Humanigen, Inc.

https://www.humanigen.com/

Latest From Humanigen, Inc.

InflaRx Looks Ahead To Late 2023 Commercial Sales For COVID-19 Antibody

The price will be more expensive than prior COVID-19 antibodies, reflecting its target to critically ill patients who are hospitalized.

Approvals Coronavirus COVID-19

Humanigen Isn’t Throwing In The Towel On Lenzilumab For COVID-19 Just Yet

The company is assessing a potential path forward in COVID-19 for the drug and is in talks with platform study groups after a Phase III study did not show statistical significance, but still showed activity.

Coronavirus COVID-19 Biologics

Publisher’s Spotlight: Citeline Awards Honor R&D Excellence

Pharma Intelligence congratulates the winners of the 2021 Citeline Awards. 

Clinical Trials Diversity & Inclusion

Publisher’s Spotlight: Citeline Awards Honor R&D Excellence

Pharma Intelligence congratulates the winners of the 2021 Citeline Awards. 

Clinical Trials Diversity & Inclusion
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • KaloBios Pharmaceuticals, Inc.
    • Humanigen Australia Pty Ltd
UsernamePublicRestriction

Register